Heartwire -- A year of treatment with valsartan (Diovan, Novartis) in patients initially in sinus rhythm after at least one prior episode of atrial fibrillation (AF) failed to suppress the arrhythmia in what’s said to be the first large, randomized, placebo-controlled test of a secondary-prevention strategy that had once seemed promising based on less definitive studies.
